Health ❯ Obesity

Weight Loss

Medications Pharmaceuticals Pharmaceutical Treatments Bariatric Surgery Medication GLP-1 Drugs Clinical Trials Surgery GLP-1 Medications Weight Loss Drugs Injections Treatment Options Dietary Interventions Pharmacology Physical Activity Medical Treatments Lifestyle Changes Surgical Interventions Semaglutide Interventions Pharmaceutical Innovations Clinical Studies Treatment Strategies Treatment Methods Fitness Programs Fitness Drug Comparison Psychological Effects Hormonal Regulation Weight Maintenance Bariatric Treatments Diet Quality Improvement Text Messages Weight Regain Weight Loss Camps Personal Struggles Metagenomics Research Trials Medicines Diabetes Treatment Dietary Supplements Drug Development Exercise Therapeutic Approaches Medical Devices Appetite-Suppressants Physical Health Rybelsus, Danuglipron, Orforglipron Tirzepatide Appetite Suppression Clinical Outcomes Weight Management Prescription Medications Medication Adherence Drug Efficacy Patient Care Men's Health Weight Loss Treatments Drug Treatments Calorie-Deficit Diet Diet, Exercise Treatment Side Effects Body Weight Reduction Personal Transformation Wegovy Intermittent Energy Restriction Fitness Journey Anti-obesity Drugs Diet Companies Physiological Parameters Effects of Tirzepatide Comorbidities Caloric Restriction Dietary Education Research Medical Conditions Health Complications Research Studies Thermogenesis Side Effects Misperceptions about Disease Management Pharmaceutical Drugs Medication Access Mounjaro Drug Trials Biological Responses Weight Loss Surgery Pharmacological Treatments Caloric Expenditure GLP-1 Hormone Weight Loss Journey Weight Loss Medications Artificial Sweeteners Weight Loss Injections Behavioral Economics Brain-Gut Microbiome Interplay Mental Challenges Exercise Impact Appetite Regulation Dietary Changes

GLP-1 Drugs Reshape Obesity Care

High prices, patchy insurance, temporary policy fixes limit patient access to GLP-1 medicines.

Tirzepatide Raises Imaging Signals of Brown Adipose Tissue in Small Randomized Trial

Penn Study Finds About 30% Lower Breast Cancer Rates Associated With GLP‑1 Use

AHA Says Exercise Should Be Prescribed as Core Part of Obesity Care

Semaglutide Causes Weight Loss by Raising cAMP in Hindbrain Neurons, NIH Study Finds

Study Finds 8,500 Daily Steps Help People Keep Weight Off After Dieting

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

GLP-1 Weight-Loss Draws Harsher Stigma Than Lifestyle Change, Study Finds

AI Review of 400,000 Reddit Posts Flags Possible GLP-1 Side Effects Beyond the Gut

Zealand Plunges as Roche Obesity Drug Posts 10.7% Weight Loss With Placebo‑Like Tolerability

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Eli Lilly Builds $1.5 Billion Stockpile of Orforglipron as FDA Decision Nears

WHO-Backed Reviews Affirm GLP-1 Weight-Loss Gains as Clinicians Flag Safety and Nutrition Gaps

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

‘My 600-lb Life’ Alum Charity Pierce Dies at 50

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Oprah Winfrey Recasts Obesity as Disease in New Book, Backs GLP-1s as Long-Term Care

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning